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Introduction
============

The potential of a new drug to prolong the QT interval is a major safety concern evaluated extensively during non-clinical and clinical drug development because it is a significant risk factor for torsade de pointes (TdP), a polymorphic ventricular arrhythmia that can be either self-limiting or, in some cases, lethal (Shah, [@b31]; Darpo, [@b6]; Pollard *et al*., [@b26]). Drug-induced prolonged QT intervals in humans are usually caused by the drug\'s ability to inhibit IK~r~, the rapid component of the delayed rectifier potassium current. In humans, this component is encoded by human ether-a-go-go related gene (hERG), also known as K~v~11.1 (KCNH2; Redfern *et al*., [@b30]). New drugs are evaluated for IK~r~ inhibitory potency using voltage clamp studies of hERG function *in vitro*, and their ability to prolong QT intervals in humans is evaluated in a non-rodent animal model (Redfern *et al*., [@b30]; Hanson *et al*., [@b14]; Pollard *et al*., [@b26]) in accordance with non-clinical \[International Conference on Harmonization (ICH) S7B\] and clinical (ICH E14) guidelines for drug-induced pro-arrhythmia (Anonymous, 2005a,b[@b3],[@b4]). These regulatory guidelines have changed the way cardiovascular safety evaluations of drug candidates are conducted and are responsible for the recent successful development of new drugs with low pro-arrhythmic risk (Park *et al*., [@b23]).

Although we understand how hERG channel inhibition can prolong ventricular action potential duration and the QT interval *in vivo*, most of this knowledge has been derived from retrospective studies of human torsadogenic drugs in animal models (Omata *et al*., [@b22]; Hanson *et al*., [@b14]). Another approach is to assess the relationship between non-clinical and clinical QT datasets for the new drugs submitted to the Food and Drug Administration (FDA) since the new ICH guidelines were implemented. The Health and Environmental Sciences Institute (HESI) Cardiovascular Pro-Arrhythmia Working Group (Pro-AWG) supported the creation of a FDA database to determine the concordance between non-clinical QT risk models and the human TQT (thorough QT/QTc study described by ICH E14) study (Trepakova *et al*., [@b35]; Pierson *et al*., [@b25]).

The Pro-AWG approach to concordance has many advantages including (i) review of a large number of pharmacologically diverse drugs, and (ii) the use of contemporary non-clinical methods to gather data, such as telemetry in conscious dogs or non-human primates (NHPs). However, a potential limitation of the FDA-TQT dataset is that it might be weighted heavily with low QT prolongation risk drugs, since drugs with a high risk for QT interval prolongation are typically terminated early in drug development (Pollard *et al*., [@b26]). This bias was substantiated by a recent TQT trend analysis that found that 78% of recent new drug submissions to the FDA (*n* = 205) had no effect on the QT interval, and most of the positive drugs exhibited only small to moderate increases in QT intervals (Park *et al*., [@b23]).

In this study, we conducted a literature search of human and animal studies on drugs with non-clinical and clinical QT interval data to assess the concordance between clinical and non-clinical study findings in a reduced-biased dataset. Past literature-based assessments of this problem have shown that non-rodent animal models accurately demonstrate QT interval prolongation and TdP caused by human therapeutics (Davis, [@b7]; De Ponti *et al*., [@b9]; Webster *et al*., [@b41]; Redfern *et al*., [@b30]). Because these prior evaluations focused on drugs with profound QT liability and torsadogenic potential (i.e. terfenadine and cisapride) that were withdrawn from human use, we looked for studies that augmented the FDA-TQT database by using drugs that may have been dropped from clinical development because of human QT prolongation risk or drugs that were developed prior to the emergence of ICH S7B and E14 guidance documents. For example, the novel dual dopaminergic-adrenergic receptor agonist Viozan™ (sibenadet) was a new chemical entity terminated in phase III clinical trials. Although non-clinical studies demonstrated no QT interval prolongation and low proarrhythmic risk, both of these phenomena occurred during human testing (Valentin *et al*., [@b36]; Newbold *et al*., [@b21]). A preliminary account of this literature review was presented in abstract form (Vargas *et al*., [@b39]).

Literature search based on text mining
--------------------------------------

The literature search was conducted to identify drugs that prolong the QT interval in both humans and animals known to respond to hERG inhibition (rabbits, guinea pigs, dogs and NHPs). Other animal species (minipigs, ferrets) were not included because of their infrequent use for QT risk assessment.

Typical literature searches rely upon specific keywords to identify publications of interest, but we used a semantics-based text-mining approach to identify relevant drugs (Spasic *et al*., [@b32]). The Safety Intelligence Program (SIP, [www.instem.com](http://www.instem.com)) was used to identify the relationships between drugs of interest and observations of QT prolongation. The SIP is an industry-sponsored initiative designed to produce assertional metadata that captures detailed relationships between drugs and biomedical findings mined from public sources. The SIP has been used to evaluate hepatic adverse events (Fourches *et al*., [@b1001]), and can evaluate other organ system findings, such as cardiovascular toxicity. The SIP uses an extensive lexicon of terms and synonyms extracted from the published literature, and is augmented with synonyms from additional sources such as ChEMBL, PubChem and Medline. The program mines text by using 'sentence-like' search statements (noun-verb-subject) that are represented in triple constructs (concept-relationship-concept). The verbal relationships between concepts are retrieved from the SIP knowledge base as assertions. In our study, the assertions describe the effect of a particular drug on the QT interval based on parts of speech (e.g. 'Cisapride_is related to QT prolongation.' The Sophia™ interface of SIP allows the user to filter the metadata by drug, literature source, species, or a variety of other criteria. We used the text-mining approach to evaluate public literature from published digital sources \[PubMed, FDA reports, the Adverse Event Reporting System (AERS), etc.\] between 1960 and 2011.

The central question of the literature search was 'What is the concordance of drug-induced QT prolongation in selected non-clinical and clinical studies?' To answer this question, a list of key words or short phrases associated with QT prolongation was compiled by searching the SIP database for matches with QT-related terms. This was followed by curation by four expert reviewers who added missing terms and subtracted non-specific terms. The final list of 180 terms or phrases (including synonyms) was then used to search the SIP database to identify a list of drugs and their relationship to the QT interval concepts in the term list. The Pro-AWG literature search followed the approach and process outlined in Figure [1](#fig01){ref-type="fig"}.

![An overview of the QTc literature search: process flow chart.](bph0172-4002-f1){#fig01}

The initial literature search yielded over 40 000 assertions on approximately 1600 drugs and combinations of drug products. The results were refined by eliminating assertions from AERS data, which is not as rigorously evaluated as data in peer-reviewed literature, and was also filtered to focus on studies that used monkeys, dogs, rabbits and guinea pigs, all of which have demonstrated sensitivity to hERG blockade QT prolongation (Redfern *et al*., [@b30]; Ando *et al*., [@b2]; Toyoshima *et al*., [@b34]; Hanson *et al*., [@b14]; Guth, [@b13]). The process yielded 591 drugs of interest that were reviewed further and curated based on predefined inclusion and exclusion criteria.

Inclusion criteria
------------------

The minimal requirement for inclusion in this literature survey was that each drug had been evaluated for its effect on the QT interval in published investigations in both humans and animal species with known sensitivity to hERG channel blockade. The QT signal could be positive (prolonged) or negative (not prolonged). The published non-clinical QT data were included irrespective of the animal model conditions (anaesthesia, restrained or unrestrained, conscious), the drug treatment protocol, the ECG methodology used to monitor the QT interval or the heart rate correction formula. The human QT data were included irrespective of study design, study duration, sample size, specific clinical subject population enrolled, QT data collection method, QT analysis extraction method or QT correction method used because the clinical QT evaluations were performed both before and after the implementation of ICH E14 requirements. The significance of the human and animal QT findings was accepted as reported.

Exclusion criteria
------------------

In this analysis, drugs were removed from consideration for several reasons, includingQT data were reported for only one species (either human or animal).The drugs were developed as class III anti-arrhythmic drugs designed to increase QT interval duration (dofetilide, ibutilide, etc.). These drugs were excluded to avoid a positive bias in the concordance analysis.Studies that evaluated the primary effect of various anaesthetics (isoflurane, pentobarbital, etc.) on ECG or QT intervals because these agents have complex effects on cardiac and neuronal electrophysiology.Human QT evaluations conducted as drug--drug interaction studies because the pharmacokinetic and pharmacodynamic factors in such studies impact study interpretation significantly.Human case reports of QT or TdP (or AERS) because these studies are not controlled, and may involve multiple drug combinations that lack a non-clinical correlate.Diagnostic pharmaceuticals and/or imaging-contrast agents (meglumine sodium diatrizoate, iohexol, etc.) because they lack a non-clinical correlate.Reports that referred to QT shortening.Protein-based therapeutics because these agents rarely prolong the QT interval (Vargas *et al*., [@b38]).

Definition of concordance
-------------------------

For the purposes of this analysis, concordance was defined as the demonstration of QT prolongation, or the absence of such an effect, in both the human and animal (one or more species) study (Valentin *et al*., [@b37]). Discordance was defined as opposite findings in humans and the animal species used in the study. The sensitivity, specificity and overall accuracy (predictability) of the non-clinical assays were calculated in percentages as (Gintant, [@b12]):Sensitivity = true positive (TP)/\[TP + false negative (FN)\]Specificity = true negative (TN)/\[TN + false positive (FP)\]Overall accuracy = (TP + TN)/(TP + TN + FP + FN)

Results
=======

The clinical-non-clinical QT dataset
------------------------------------

To calculate QT concordance, we used filters to extract and refine human and animal QT data from the literature. Applying the exclusion criteria left 171 drugs to evaluate for QT findings in the species of interest (Figure [1](#fig01){ref-type="fig"}). A more thorough review of the published reports eliminated 131 of these drugs (Figure [1](#fig01){ref-type="fig"}) because they had uninterpretable human QT findings (dosulpin, ethmozine, falipamil, etc.), they were clinical case studies instead of controlled clinical trials (doxepin, methoxamine, etc.) or they had inadequate animal QT data assessments. There were 40 drugs in the final dataset, 23 of which prolonged the QT interval in humans and 17 that did not.

It should be noted that, in an effort to expand the literature-based data, all 40 drugs were profiled for their pharmacological activity in hERG function and trafficking assays (see [Supporting Information Table S1](#sd1){ref-type="supplementary-material"}).

Concordance of clinical and non-clinical QT findings: drugs that cause QT interval prolongation
-----------------------------------------------------------------------------------------------

The 23 drugs reported to prolong the QT interval in humans came from a broad range of therapeutic classes (Table [@b1]). Some of the drugs are in current clinical use, while others were evaluated only in limited clinical trials or are no longer on the market. Ninety-one percent (21/23) of these drugs prolonged the QT interval in animal models as well (Table [@b1]), which indicates that the animal models have high sensitivity. Based on the year of publication, many of the studies included in this search were conducted prior to 2005, the year when ICH S7B and E14 were implemented (Anonymous, 2005a,b[@b3],[@b4]).

###### 

Literature search agents (23) reported to prolong the QTc interval in humans: concordance with animal QTc studies

  Agent                   Clinical use           ↑QTc human   ↑QTc animal   References[a](#tf1-2){ref-type="table-fn"}
  ----------------------- ---------------------- ------------ ------------- ---------------------------------------------------------------------------------------------------------------------------------------
  Amantadine              Antiviral              \+           \+            (h): L Wu Poisoning & Drug Overdose (KR Olson, Ed.) (2007)
                          Parkinson\'s disease                              (g): M Hiraoka *et al*. Circ Res 65:880--893 (1989).
  Arsenic trioxide        Anti-cancer            \+           \+            (h): J Zhou *et al*., Chin Med J (Engl) 116:1764--6 (2003)
                                                                            (g): HL Sun *et al*., Basic Clin Pharmacol Toxicol 98:381--8 (2006)
  Astemizole              Antihistamine          \+           \+            (h): YG Yap *et al*. Clin Allergy Immunol 17:389--419 (2002)
                                                                            (d): JJ Salata *et al*., Circ Res 76:110--19 (1995)
  Atomoxetine             Antidepressant         \+           \+            (h): STRATTERA™ (atomoxetine) FDA Review & Evaluation of Clinical Data (NDA 21--411), 2002
                                                                            (d): STRATTERA™ (atomoxetine) FDA Pharmacology Review (NDA 21--411), 2002
  Bepridil                Anti-anginal           \+           \+            (h): B Lecocq *et al*., Am J Cardiol 66:636--41.(1990)
                                                                            (d): LA Hanson *et al*., J Pharmacol Toxicol Meth 54:116--29 (2006)
  Cisapride               Antihistamine          \+           \+            (h): AD van Haarst *et al*. Clin Pharmacol Ther 64:542--6 (1998)
                                                                            (d): LA Hanson *et al*., J Pharmacol Toxicol Meth 54:116--29 (2006)
  Citric acid (citrate)   Excipient              \+           \+            (h): SJ Laspina *et al*., Transfusion 42:899--903 (2002)
                                                                            (d): T Fukuda *et al*., Clinical Nutrition 25:984--993 (2006)
  Clobutinol              Anti-tussive           \+           \+            (h): C Belloca *et al*., Mol Pharmacol 66:1093--1102 (2004).
                                                                            (g): A Takahara *et al*., J Cardiovasc Pharmacol 54:552--559 (2009)
  Dasatinib               Anti-cancer            \+           \+            (h): GS Orphanos *et al*., Acta Oncol 48:964--970 (2007).
                                                                            (r): SPRYCEL™ (dasatinib) FDA Pharmacology/Toxicology Review & Evaluation (NDA 21--986 & 22--072), 2005
  Diphenhydramine         Antihistamine          \+           −             (h): W Zareba *et al*., Am J Cardiol 80:1168--73 (1997).
                                                                            (g): JA Hey *et al*., Clin Exp Allergy 25:974--84 (1995).
                                                                            (d): S Toyoshima *et al*., J Pharmacol Sci 99:459--71 (2005); LA Hanson *et al*., J Pharmacol Toxicol Meth 54:116--29 (2006)
  Doxorubicin             Anti-cancer            \+           \+            (h): T Nousianen *et al*., J Intern Med 245:359--64 (1999).
                                                                            (r): P Milberg *et al*., Basic Res Cardiol 102:42--51 (2007)
  DPI 201-106             Inotrope               \+           \+            (h): V Kühlkamp V *et al*., J Cardiovasc Pharmacol 42:113--117 (2003).
                                                                            (d): MJ Walker *et al*., J Cardiovasc Pharmacol 14:381--388 (1989).
  Famotidine              Antihistamine          \+           −             (h): KW Lee *et al*., Am J Cardiol 93:1325--7 (2004).
                                                                            (d): A Sugiyama *et al*., Eur J Pharmacol 466:137--46 (2003)
  Haloperidol             Antipsychotic          \+           \+            (h): PJ Weiden *et al*., J Clin Psychopharmacol 28:S12--9 (2008)
                                                                            (d): S Toyoshima *et al*., J Pharmacol Sci 99:459--71 (2005)
  Melperone               Antipsychotic          \+           \+            (h): WK Hui *et al*., J Cardiovasc Pharmacol 15:144--9 (1990); C Stollberger *et al*., Int Clin Psychopharmacol 20(5):243--51 (2005).
                                                                            \(d\) ES Platou *et al*., Can J Physiol Pharmacol 64:1286--90 (1986)
  Papaverine              Anti-anginal           \+           \+            (h): MJ Kern *et al*., Cathet Cardiovasc Diagn 19:229--36 (1990).
                                                                            (d): CW Christensen *et al*., Circulation 83:294--303 (1991)
  Pentamidine             Anti-protozoal         \+           \+            (h): MD Eisenhauer *et al*., Chest 105:389--395 (1994).
                                                                            (d): H Yokoyama *et al*., J Pharmacol Sci 110:476--82 (2009)
  Pimozide                Antipsychotic          \+           \+            (h): G Fulop *et al*., Am J Psychiatry 144:673--675 (1987)
                                                                            (d): LA Hanson *et al*., J Pharmacol Toxicol Meth 54:116--29 (2006)
  Probucol                Anti-hyperlipidemia    \+           \+            (h): KF Browne *et al*., Am Heart J 107:680--4 (1984)
                                                                            (m): JE Lebeau. Nouv Presse Med 9:3001--4 (1980)
  Sildenafil              Erectile dysfunction   \+           \+            (h): J Morganroth *et al*., Am J Cardiol 93:1378--83 (2004)
                                                                            (d): O Nagy *et al*., Br J Pharmacol 141:549--51 (2004)
  Tacrolimus              Immuno-suppression     \+           \+            (h): SP Hodak *et al*., Transplantation 66:535--7 (1998); MC Johnson *et al*., Transplantation 53:929--30 (1992)
                                                                            (g): T Minematsu *et al*., Pharmacokinet Pharmacodyn 28:533--54 (2001)
  Terfenadine             Antihistamine          \+           \+            (h): BP Monahan *et al*., JAMA. 264:2788--2790 (1990)
                                                                            (d): LA Hanson *et al*., J Pharmacol Toxicol Meth 54:116--29 (2006)
  Thioridazine            Antipsychotic          \+           \+            (h): AH Glassman & JT Bigger Jr. Am J Psychiatry 158:1774--82 (2001)
                                                                            (d): LA Hanson *et al*., J Pharmacol Toxicol Meth 54:116--29 (2006)

The reference corresponds to a representative QTc study conducted in humans (h), primates (m), dogs (d), rabbits (r), guinea pigs (g).

The analysis showed that diphenhydramine and famotidine demonstrated discordance between the reported clinical and non-clinical QT data, that is, a QT-positive signal was identified in a human QT study, but not in an animal cardiovascular safety model (dogs and guinea pigs for diphenhydramine and dogs for famotidine). A general observation was dogs were used frequently in non-clinical QT evaluation studies.

Concordance of clinical and non-clinical QT findings: drugs that have no effect on the QT interval
--------------------------------------------------------------------------------------------------

The literature review identified 17 drugs that did not prolong the QT interval in humans (Table [@b2]). Fifteen of these drugs (88%) also did not prolong the QT interval in an animal model (Table [@b2]), which indicates that the animal models have high specificity. Nifedipine and verapamil did not prolong the QT interval in humans but did prolong it in a conscious telemetered dog model.

###### 

Literature search agents (17) reported to have no effect on the QTc interval in humans: concordance with animal QTc studies

  Agent             Clinical use           ↑QTc human   ↑QTc animal   References[a](#tf2-1){ref-type="table-fn"}
  ----------------- ---------------------- ------------ ------------- --------------------------------------------------------------------------------------------------------------------
  Alinidine         Negative chronotrope   −            −             (h): UW Wiegand *et al*., J Cardiovasc Pharmacol 4:59--62 (1982)
                                                                      (d): Traunecker W, Walland A, Arch Int Pharmacodyn Ther 244:58--72 (1980)
  Almotriptan       Anti-migraine          −            −             (h): M Boyce *et al*., J Cardiovasc Pharmacol 37:280--289 (2001)
                                                                      (d): J Gras *et al*., Eur J Pharmacol 410:53--59 (2000)
  Amlodipine        Anti-hypertensive      −            −             (h): K Porthan *et al*., Ann Med 41:29--37 (2009).
                                                                      (d): M Fujisawa *et al*., J Cardiovasc Pharmacol 53:325--32 (2009)
  Amoxicillin       Antibiotic             −            −             (h): T Omata *et al*., J Pharmacol Sci 99:531--541 (2005)
                                                                      (d): S Toyoshima *et al*., J Pharmacol Sci 99:459--71 (2005)
  Amrinone          Positive Inotrope      −            −             (h): GV Naccarelli *et al*., Am J Cardiol 54:600--4 (1984)
                                                                      (d): G Onuaguluchi *et al*., Arch Int Pharmacodyn Ther 264:263--73 (1983)
  Aspirin           Analgesic              −            −             (h): AM Tonkin Aust N Z J Med 22:631--635 (1992).
                                                                      (d): LA Hanson *et al*., J Pharmacol Toxicol Meth 54:116--29 (2006)
                                                                      (r): LM Hondeghem & P Hoffman J Cardiovasc Pharmacol 41:14--24 (2003).
  Captopril         Anti-hypertensive      −            −             (h): T Omata *et al*., J Pharmacol Sci 99:531--541 (2005)
                                                                      (d): S Toyoshima *et al*., J Pharmacol Sci 99:459--71 (2005)
  Ceterizine        Antihistamine          −            −             (h): R Hulhoven *et al*., Eur J Clin Pharmacol 63:1011--1017 (2007).
                                                                      (d): J Weissenburger *et al*., Clin Exp Allergy 29(Suppl 3):190--196 (1999).
  Cilnidipine       Anti-hypertensive      −            −             (h): N Ashizawa *et al*., International Society for Hypertension (ISH) -- Hypertension Sydney Abstract 468 (2012).
                                                                      (d): A Takahara *et al*., Br J Pharmacol 158:1366--1374 (2009).
  Ciprofloxacin     Antibiotic             −            −             (h): JP Tsikouris *et al*. Ann Noninvasive Electrocardiol 11:52--56 (2006).
                                                                      (d): S Toyoshima *et al*. J Pharmacol Sci 99:459--471 (2005)
  Enalapril         Anti-hypertensive      −            −             (h): FJ Seara *et al*., Ann Noninvasive Electrocardiol 8:47--54 (2003)
                                                                      (g): P Hess *et al*., Lab Anim 41:470--80 (2007)
  Enalaprilat       Anti-hypertensive      −            −             (h): H Bonnemeier *et al*., Pacing Clin Electrophysiol 30:631--7 (2007)
                                                                      (r): A Kijtawornrat *et al*., J Pharmacol Toxicol Methods 53:168--73 (2006)
  Ibandronic acid   Osteoporosis           −            −             (h): BONIVA™ (ibandronate sodium) FDA Clinical Pharmacology & Biopharmaceutics Review (NDA 21--858), 2005
                                                                      (d): BONIVA™ (ibandronate sodium) FDA Clinical Pharmacology & Biopharmaceutics Review (NDA 21--858), 2005
  Mefloquine        Anti-malarial          −            −             (h): M Bindschedler *et al*., Eur J Clin Pharmacol 56:375--81 (2000)
                                                                      (r): ID Lightbown *et al*., Br J Pharmacol 132:197--204 (2001)
  Nifedipine        Anti-hypertensive      −            \+            (h): L Alberio *et al*., Schweiz Med Wochenschr 122:1723--7 (1992)
                                                                      (d): S Toyoshima *et al*., J Pharmacol Sci 99:459--471 (2005)
  Propranolol       Anti-hypertensive      −            −             (h): PE Puddu *et al*. Br Heart J 44:604--605 (1980).
                                                                      (d): LA Hanson *et al*., J Pharmacol Toxicol Meth 54:116--29 (2006)
  Verapamil         Anti-hypertensive      −            \+            (h): JL Holtzman *et al*., Clin Pharmacol Ther 46:26--32 (1989)
                                                                      (d): S Toyoshima *et al*., J Pharmacol Sci 99:459--471 (2005)

The reference corresponds to a representative QTc study conducted in humans (h), primates (m), dogs (d), rabbits (r), guinea pigs (g).

Discussion
==========

This retrospective literature-based review examined the relationship between non-clinical (non-rodent animal) and human QT interval responses to a variety of drugs to determine whether non-clinical findings could accurately predict human cardiovascular reactions to new pharmaceuticals. It appears that there is excellent concordance between human and animal findings for drugs that increase or do not alter the QT interval. Ninety-one percent of the drugs that prolong the QT interval in humans also did so in animals (guinea pigs, rabbits, dogs, non-human primates), and 88% of the drugs that did not prolong the QT interval in humans also did not prolong the interval in animals. Our search found that non-clinical QT assays have an overall accuracy to predict human responses 90% of the time. Only four drugs (10%) in the review produced different QT interval responses in humans and animals, and these discrepancies have reasonable explanations (see below).

The need to determine whether non-clinical QT assays in animals can predict whether or not a drug will prolong the QT interval in humans has always been essential, and has increased since regulatory guidance now recommends specific non-clinical and clinical approaches to QT prolongation risk evaluation (Anonymous, 2005a,b[@b3],[@b4]; Pugsley *et al*., [@b27]; Trepakova *et al*., [@b35]). Prior to the implementation of the ICH S7B and E14 regulatory guidance documents on QT assessment, other retrospective analyses of the literature were performed to determine whether safety studies of human cardiovascular drugs performed in animals and general toxicology study findings could predict human QT prolongation (Davis, [@b7]; De Ponti *et al*., [@b9]; Redfern *et al*., [@b30]). These analyses typically focused on drugs known to cause profound QT prolongation and TdP in human subjects. For instance, Davis ([@b7]) gave a high-level report on nine non-cardiac medications (astemizole, cisapride, erythromycin, probucol, risperidone, sertindole, sparfloxacin, terfenadine and terodiline) approved for human use, which were found to cause QT prolongation consistently in telemetered dog and monkey safety studies. Davis ([@b7]) only identified non-clinical reports of concordance for each drug, and did not assess models or integrate plasma drug levels to account for exposure difference across species. No examples of discordance were identified, so the animal models used were accurate predictors of human QT behaviour for this short list of high-risk drugs. De Ponti *et al*. ([@b9]) used Medline to assemble an extensive list of drugs associated with clinical QT prolongation and TdP. Their analysis included literature-based references to *in vitro* and *in vivo* non-clinical reports of delayed repolarization (IK~r~/hERG potency and QT prolongation in an animal model), but no attempt was made to assess the concordance between clinical and non-clinical QT findings. The Redfern report (2003) was a broader review of the literature that focused on 52 drugs with a range of QT liability including very low QT and TdP risk. A feature of that analysis was the inclusion of animal and human exposure data on drug concentrations that cause hERG blockade and QT prolongation *in vivo*.

Identification of known QT-prolonging drugs with the text-mining approach
-------------------------------------------------------------------------

The current literature survey identified approximately 1600 drugs (or chemicals) that contained a reference to a QT interval (or delayed cardiac repolarization, ventricular arrhythmia or TdP) that was affected or not affected by a drug administered to a human or animal subject. This was an unexpectedly large number of citations, given prior publications that generated lists of drugs associated with QT prolongation and TdP. Three of these reports (De Ponti *et al*., [@b9]; Shah, [@b31]; Redfern *et al*., [@b30]) are often cited in the literature, and many of the drugs in those publications were detected by text mining. Of the 118 drugs reported by Shah, 101 (86%) were identified in the current analysis (missed drugs: acodazole, amsulalol, arteether, N-acetyl-proacainamide, butriptyline, chlorprothixene, dothiepin, D0870, fendiline, nifenalol, triethylperazine, trifluoperidol, penfluridol, pipamperone, S9788, thiothixene and tiapride). The text-mining approach identified 96% (132 of 137) of the drugs cited by De Ponti (missed drugs: clindamycin, dexfenfluramine, fenoxedil, pyrilamine, tiapride) and 100% of the drugs evaluated by Redfern. This indicates that the text search strategy can evaluate a large volume of literature and was able to detect agents that prolong QT intervals through direct (e.g. terfenadine, cisparide, haloperidol) and indirect (e.g. arsenic, pentamidine, citric acid) mechanisms of action on cardiac repolarization. The small number of missed drugs could reflect the error rate associated with text-mining approaches in general, the error rate associated with the analysis product (SIP), or the differences in the QT data sources and search strategies previously used (De Ponti *et al*., [@b9]; Shah, [@b31]).

Examples of QT discordance
--------------------------

The analysis identified four examples of discordance between human and animal studies. Diphenhydramine is a widely used antihistamine that weakly inhibits the hERG channel but can produce TdP (Woosley, [@b43]; Khalifa *et al*., [@b15]). Doses of diphenhydramine greater than 500 mg are associated with QT interval prolongation but not TdP in humans (Zareba *et al*., [@b44]), and do not prolong the QT interval in guinea pigs and dogs (Table [@b1], [Supporting Information Table S1](#sd1){ref-type="supplementary-material"}). This discordant finding is likely related to the high doses of the drug given to human study subjects that are not reproduced in animal trials, but we lack drug exposure data to assess the difference.

A similar scenario could explain the differences in QT interval prolongation observed in human and animal models after famotidine exposure. Famotidine, which at therapeutic doses is associated with QT prolongation and TdP in humans, tests negative in animal models. The basis for this difference is unknown, but a metabolite may be responsible for QT interval prolongation, especially given the profile of this drug in hERG function and trafficking assays (Sugiyama *et al*., [@b33]; Nakamura *et al*., [@b20]; [Supporting Information Table S1](#sd1){ref-type="supplementary-material"}).

An example of a drug with low QT interval prolongation risk in humans and a false positive signal in animals was nifedipine, an L-type calcium channel blocker that is a potent arterial vasodilator and is used to treat hypertension and angina. Since the formula for QT interval correction is affected when the heart rate is elevated or reduced (Matsunaga *et al*., [@b18]; Raunig *et al*., [@b28]), it is possible that the QT interval prolongation observed in dogs following a 3 mg·kg^−1^ dose of nifedipine was caused by the concomitant reflex tachycardia (Toyoshima *et al*., [@b34]). This hypothesis is supported by the findings that nifedipine had no inhibitory effect on hERG current or channel trafficking at supra-therapeutic concentrations *in vitro* ([Supporting Information Table S1](#sd1){ref-type="supplementary-material"}).

The confounding influence of heart rate elevation on QT correction may also contribute to the complex QT effects (increase and decrease) observed with verapamil in dogs (Toyoshima *et al*., [@b34]). Verapamil is an equipotent antagonist of both hERG and L-type calcium channels (Zhang *et al*., [@b45]) and this 'mixed channel pharmacology', which can cause coincident prolongation and shortening of the QT interval, is thought to be the reason why QT prolongation and TdP are not observed clinically at therapeutic exposures. In the dog telemetry model, the onset of reflex tachycardia (in response to hypotension caused by vascular calcium channel blockade) also confounds the interpretation of QT interval changes (Fridericia\'s formula) seen following verapamil administration (Toyoshima *et al*., [@b34]). It should be noted that verapamil increased the QT interval in dogs, but only when the Bazett correction was used (Hanson *et al*., [@b14]).

Limitations of the text-mining approach
---------------------------------------

The text mining-based literature search effectively identified many QT interval prolonging drugs that had been previously identified in similar searches of humans and non-clinical models (De Ponti *et al*., [@b9]; Shah, [@b31]; Redfern *et al*., [@b30]; Omata *et al*., [@b22]). We believe that this literature search approach was comprehensive, but recognize that it may have imperfectly detected all the drugs associated with QT prolongation in human studies.

Despite the use of extensive text-mining vocabularies, the ability of text mining to detect key words or terms and relationships in complex sentences with large separations between primary search terms, or studies that use non-standard keyword synonyms not seen in clinical QT reports means that some drugs will go undetected. Published reports that lack a specific species in the document metadata could also account for the failure of a drug to meet inclusion criteria.

A challenge of any literature analysis is whether 'all the relevant data' has been cited and captured appropriately. As indicated by De Ponti *et al*. ([@b9]), it may be valuable to create a registry of known drugs that have been studied for their QT liability in humans, along with relevant non-clinical evidence that pertains to QT risk assessment. Such a registry would be accessible to all parties interested in QT liability assessment and would increase our understanding of *in vitro* and *in vivo* non-clinical cardiac repolarization models. The TQT database developed at the FDA, in partnership with the HESI Pro-AWG, could be the framework for creating such a registry (Trepakova *et al*., [@b35]; Pierson *et al*., [@b25]).

Limitations of the concordance analysis
---------------------------------------

A significant limitation of the current work is that exposure data in humans and animals was not integrated into the concordance analysis because plasma drug concentrations (C~max~) were not cited in the literature reviewed. As a result, the relationship between drug exposure (total and free) across species and models is uncertain. The evaluation of drug exposure data, especially free drug concentrations, is invaluable for understanding the relationship between drug levels and the degree of hERG blockade ([Supporting Information Table S1](#sd1){ref-type="supplementary-material"}) and QT interval prolongation *in vivo*, and helps develop a quantitative assessment of concordance based on exposure parameters (Redfern *et al*., [@b30]).

Gathering pharmacokinetic data for the parent molecule as well as determining the contribution of metabolites to observed QT interval prolongations, would require a separate effort and was beyond the scope of this particular QT concordance exercise. This is a key limitation that reduces the current analysis to a binary assessment of the presence or absence of a QT interval prolongation signal. Therefore, any statements about QT interval concordance between clinical and non-clinical models are qualitative assessments and come from the agreement between human and animal QT interval studies.

Another caveat of this analysis is the focus on QT interval measurements as a surrogate for TdP. Other parameters, such as T-wave morphology changes or markers of T-wave dispersion of repolarization (Tpeak-Tend) were not considered, but might have been a valuable addition to the assessment. Lastly, there is the potential for publication bias, which is inherent in any literature evaluation.

Conclusions
===========

This literature review used a text-mining approach to identify drugs that affected or did not affect the QT interval in both humans and animals. There was a 90% agreement (overall accuracy) between the animal and human findings for the drugs identified. The key message is that evaluation of new drugs in non-rodent animal cardiovascular models can be used to predict human QT interval prolongation risk. The overall findings from this literature analysis are in complete agreement with a recent cross-company data-sharing initiative, which demonstrated that the conscious dog telemetry model was valuable for predicting QT outcomes in a phase 1 clinical study (Ewart *et al*., [@b11]; *n* = 113 small molecules in dataset). Investigators should be aware, however, that QT prolongation can be the result of non-hERG channel-mediated mechanisms, indirect changes in autonomic nerve tone into the heart, altered channel density or properties, heart rate over-correction, and the emergence of metabolites. The underlying mechanisms of a QT interval result must be understood before QT risk can be accurately assessed.
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AERS

:   Adverse Events Reporting System

FDA

:   Food and Drug Administration

FN

:   false negative

FP

:   false positive

hERG

:   human ether-a-go-go related gene

HESI

:   Health and Environmental Sciences Institute

ICH

:   International Conference on Harmonization

NHP

:   non-human primate

Pro-AWG

:   Cardiovascular Pro-Arrhythmia Working Group

SIP

:   Safety Intelligence Program

TdP

:   torsade de pointes

TN

:   true negative

TP

:   true positive

TQT

:   thorough QT/QTc study described by ICH E14
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**Table S1** Inhibitory potency values in the hERG function and trafficking assays.
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